Histogen Inc

Histogen — Conatus Pharmaceuticals — Corporate Update (April 2019)

30 slides from Histogen's corporate update, Apr 2, 2019

  1. Slide 1: Company Update

    NASDAQ CNAT Company Update Striving to improve human health April 2, 2019

  2. Slide 2: Forward-looking Statements

    2 April 2, 2019 | Company Update Forward - looking Statements This presentation contains forward - looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, busi

  3. Slide 3: Conatus at a Glance

    3 April 2, 2019 | Company Update Conatus at a Glance Lead in - licensed compound emricasan has the potential to modify liver disease outcome Novartis partnership fully funds any further emricasan development Lead internally developed compound CTS - 2090 targeted for clinical testing 1H20 Capital at

  4. Slide 4: Emricasan – Targeting Unmet Need in Liver Disease

    4 April 2, 2019 | Company Update Emricasan – Targeting Unmet Need in Liver Disease Profile Orally administered Actively transported into the liver Not metabolized in the liver Addresses all etiologies of cirrhosis First - in - class pan - caspase inhibitor ideally suited to treat liver disease Effic

  5. Slide 5: Phase 2b ENCORE-PH Trial

    5 April 2, 2019 | Company Update Phase 2b ENCORE - PH Trial Extension 24 - week treatment/placebo continuation Following for liver function and clinical outcomes In NASH Cirrhosis Patients with Severe Portal Hypertension EmricasaN , a Caspase inhibitOR , for Evaluation in Portal Hypertension Top - l

  6. Slide 6: Phase 2b ENCORE-LF Trial

    6 April 2, 2019 | Company Update Phase 2b ENCORE - LF Trial Evaluating Clinical Outcomes in NASH Cirrhosis Patients with Impaired Liver Function Primary Endpoint Event - free survival, free from: 01 All - cause mortality 02 New decompensation events 03 ≥4 points MELD score progression Top - line res

  7. Slide 7: Phase 2b Trials Define Distinct Paths to NASH Cirrhosis Market

    7 April 2, 2019 | Company Update Phase 2b Trials Define Distinct Paths to NASH Cirrhosis Market Ongoing P2b Trial Endpoint Clinical Benefit Market ENCORE - PH Extension Compensated or early decompensated cirrhosis with severe portal hypertension Liver Function Clinical Outcomes Improve portal hypert

  8. Slide 8: Medical Need and Diagnosis Rates Drive Value in Cirrhosis

    8 April 2, 2019 | Company Update Medical Need and Diagnosis Rates Drive Value in Cirrhosis *Estes C et al J Hepatol 2018 / analyst reports. Assumes diagnosis rate of 13% for early fibrosis, 17% for advanced fibrosis and 84% for cirrhosis. 2030 U.S. NASH PATIENT ESTIMATES US Patients Early Fibrosis F

  9. Slide 9: CTS-2090 Inflammasome Diseases

    CTS - 2090 Inflammasome Diseases

  10. Slide 10: IL-1β Blocking Agents – Set the Stage for Next Generation Products

    10 April 2, 2019 | Company Update IL - 1 β Blocking Agents – Set the Stage for Next Generation Products • Multiple approved biologic agents that block IL - 1 β – Canakinumab ( Ilaris ® ) – Anakinra (Kineret ® ) – Rilonacept ( Arcalyst ® ) • Global sales of over $700 million in 2018 • Approved rare d

  11. Slide 11: IL-1β Driven by Multiple Inflammasomes

    11 April 2, 2019 | Company Update IL - 1 b - Driven by Multiple Inflammasomes Solberger G, et al. Innate Immun. 2014, p115 - 125.

  12. Slide 12: Disease Areas Implicated in the Inflammasome Pathway

    12 April 2, 2019 | Company Update Disease Areas Implicated in the Inflammasome Pathway Therapeutic areas Disease Conditions Oncology NSCLC Breast Cancer Melanoma Hepatology NASH Autoimmune Hepatitis PSC (POLT) a - ATTD Alcoholic Hep Respiratory Steroid Resistant Asthma COPD IPF Acute Lung Injury Ren

  13. Slide 13: IL-1β Blocking Agents – Development Pathway Defined

    13 April 2, 2019 | Company Update IL - 1 b Blocking Agents – Development Pathway Defined* • Wide scope of clinical indications and therapeutic validation • All agents given by injection (not orally active) • Most recent success – Novartis, Ilaris ® 2017: C anakinumab An ti - inflammatory T hrombosis

  14. Slide 14: The Future of IL-1β Blocking May Be in Cancer

    14 April 2, 2019 | Company Update The Future of IL - 1 β Blocking May Be in Cancer

  15. Slide 15: Inflammasome Companies: Investor and Pharma Interest

    15 April 2, 2019 | Company Update Inflammasome Companies: Investor and Pharma Interest • Jecure Therapeutics raised a $30mm Series A from Versant in 2017. Acquired by Genentech in 2018. • Inflazome closed a $17mm Series A in 2016 from Novartis Venture Fund and others. Recently closed a $46mm Series

  16. Slide 16: Caspase 1 Inhibitors Target Inflammasome Pathway at Optimal Intervention Point

    16 April 2, 2019 | Company Update Caspase 1 Inhibitors (Novartis) (Amgen) ( Regeneron ) Caspase 1 Inhibitors Caspase 1 Inhibitors Target Inflammasome Pathway at Optimal Intervention Point We believe a caspase 1 selective small molecule inhibitor can be a safe and efficacious agent for intervention i

  17. Slide 17: Targeting IL-1β and Inflammation via Caspase Inhibition

    17 April 2, 2019 | Company Update Targeting IL - 1 b and Inflammation via Caspase 1 Inhibition IL - 1 b is a validated inflammatory target – high interest in the pathway NLRP3 Caspase 1 IL - 1 β Pro caspase 1 Pro IL - 1 β Inflammation NLRP3 companies Biologic products (Novartis) (Amgen) (Regeneron)

  18. Slide 18: Caspase-Inhibition Improves Survival Better than Blocking IL-1β, IL-18 or Both

    18 April 2, 2019 | Company Update Caspase - 1 Inhibition Improves Survival Better than Blocking IL - 1 β , IL - 18 or Both • Constitutively active NLRP3 (FCAS model) results in chronic activation of caspase 1 – Leads to production of IL - 1 β and IL - 18 – Leads to pyroptotic cell death via gasdermi

  19. Slide 19: Conatus Caspase Inhibitor Portfolio

    19 April 2, 2019 | Company Update Conatus Caspase 1 Inhibitor Portfolio • Designed highly selective caspase 1 inhibitors – Incorporated novel chemistry to remove activity against apoptotic caspases – Maintained sub - nanomolar activity against caspase 1 – Inhibits downstream IL - 1 b (a clinically v

  20. Slide 20: Conatus' Lead Caspase Inhibitor: CTS-2090

    20 April 2, 2019 | Company Update Conatus’ Lead Caspase 1 Inhibitor: CTS - 2090 • Potency – Sub - nanomolar IC 50 against human caspase - 1 – Sub - micromolar IC 50 in THP 1 cells • Selectivity – Broad panel of receptors and enzymes, >100,000 fold selectivity over caspase 1 – No anti - apoptotic act

  21. Slide 21: Caspase Selectivity Profile Validated in Cell-based Functional Assays

    21 April 2, 2019 | Company Update Caspase Selectivity Profile Validated in Cell - based Functional Assays • CTS - 2090 is a potent inhibitor of LPS - stimulated NLRP3 driven IL - 1 b production in THP 1 cells • IC 50 value similar to that of the potent pan - caspase inhibitor, IDN - 7314 • CTS - 209

  22. Slide 22: Pathway Inhibition in Mouse Gout Model of Crystal-induced IL-1β Production

    22 April 2, 2019 | Company Update Pathway Inhibition in Mouse Gout Model of Crystal - induced IL - 1 b Production • Reduces IL - 1 b levels to the same extent and at a lower oral dose than the NLRP3 standard inhibitor MCC950 in the MSU model of gout – Oral administration of CTS - 2090 at 10 mg/kg. O

  23. Slide 23: CTS-2090: Caspase Selectivity Profile Validated in vivo

    23 April 2, 2019 | Company Update CTS - 2090: Caspase 1 Selectivity Profile Validated in vivo • Consistent with cellular and enzymatic selectivity profiles – CTS - 2090 does not protect against a Fas induced apoptosis in mice • Oral administration at 10mg/kg – IDN - 7314 is fully protective against

  24. Slide 24: Autoinflammatory Diseases as Initial Clinical Target for CTS-2090

    24 April 2, 2019 | Company Update Autoinflammatory Diseases as Initial Clinical Target for CTS - 2090 • Single - gene mutations that activate inflammasomes and result in IL - 1 β production • Spectrum of diseases with variable organ system involvement, severity and age of onset – Cryopyrin - associa

  25. Slide 25: Overview of CTS-2090 Development Plan

    25 April 2, 2019 | Company Update Overview of CTS - 2090 Development Plan PK, Safety, Tolerability Phase 1, part A Single - dose PK Phase 1, part B Multiple - dose PK Phase 2a Multiple - dose/endotoxin Phase 2 PoC Autoinflammatory Diseases Other Potential Indications • Gout flares • Oncology • IBD/C

  26. Slide 26: Highlights of Conatus Approach

    26 April 2, 2019 | Company Update Highlights of Conatus Approach • Like inflammasome intervention, caspase 1 inhibition is a small molecule strategy to block the formation of IL - 1 b • Additional benefits include IL - 18 inhibition, gasdermin D inhibition, and a decrease in inflammation driven cell

  27. Slide 27: Expanded Pipeline Addressing Underserved Chronic Disease Markets

    27 April 2, 2019 | Company Update Program (Indication) Preclinical Phase 1 Phase 2 Milestone *Emricasan ENCORE - PH (NASH Cirrhosis) Phase 2b extension data expected mid - 19 *Emricasan ENCORE - LF (NASH Cirrhosis) Phase 2b top - line data expected mid - 19 CTS - 2090 Caspase - 1 Inhibitor (Inflamma

  28. Slide 28: Financial Snapshot

    28 April 2, 2019 | Company Update Financial Snapshot Cash, cash equivalents & marketable securities as of 12/31/18 $40.7 million Debt – * Shares outstanding as of 12/31/18 33.2 million Projected cash, cash equivalents & marketable securities year - end 2019 $10 – 15 million *Novartis note converted

  29. Slide 29: Conatus at a Glance

    29 April 2, 2019 | Company Update Conatus at a Glance Lead in - licensed compound emricasan has the potential to modify liver disease outcome Novartis partnership fully funds any further emricasan development Lead internally developed compound CTS - 2090 targeted for clinical testing 1H20 Capital at

  30. Slide 30: NASDAQ CNAT Striving to improve human health

    NASDAQ CNAT Company Update Striving to improve human health April 2, 2019

Conatus Pharmaceuticals — Corporate Update (April 2019) on 6ix